You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cyclophosphamide、Prednisone、Thalidomide(CPT)

Showing 1 - 25 of 3,161
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multicentric Castleman Disease Trial in Beijing (Thalidomide, cyclophosphamide and prednisone)

Unknown status
Has Results
  • Multicentric Castleman Disease
  • Thalidomide, cyclophosphamide and prednisone
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Apr 5, 2020

Relapse/Refratory Peripheral T Cell Lymphoma Trial in HuaiAn, WuXi (C-CPT)

Unknown status
  • Relapse/Refratory Peripheral T Cell Lymphoma
  • HuaiAn, Jiangsu, China
  • +1 more
Jan 7, 2019

Plasma Cell Myeloma Trial in Israel, United States (Laboratory Biomarker Analysis, Lenalidomide, Melphalan)

Active, not recruiting
Has Results
  • Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +5 more
  • Mobile, Alabama
  • +392 more
Jan 25, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (lenalidomide, Placebo, Rituximab)

Completed
Has Results
  • Lymphoma, Large B-Cell, Diffuse
  • Fayetteville, Arkansas
  • +431 more
Nov 17, 2022

High-risk Large B-cell Lymphoma (LBCL) Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • High-risk Large B-cell Lymphoma (LBCL)
  • Axicabtagene Ciloleucel
  • +7 more
  • (no location specified)
Dec 13, 2022

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma Trial in Australia, Canada,

Completed
Has Results
  • Localized Resectable Neuroblastoma
  • +4 more
  • Clinical Observation
  • +5 more
  • Birmingham, Alabama
  • +103 more
Jan 4, 2023

Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)

Not yet recruiting
  • Large B-Cell Lymphoma
  • Xi'an, China
    First Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023

Diffuse Large B Cell Lymphoma Trial in Zhengzhou (Rituximab, Lenalidomide, Cyclophosphamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Seattle (drug, other, biological)

Completed
Has Results
  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 18, 2022

Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Apr 24, 2022

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma, Chronic Kidney Disease Trial in United Kingdom (Bortezomib, Thalidomide, Bendamustine)

Completed
Has Results
  • Multiple Myeloma
  • Chronic Kidney Disease
  • Basingstoke, United Kingdom
  • +8 more
Jan 26, 2022

Stress Disorders, Post-Traumatic Trial in Boston (Adjunctive writing to amplify response and engagement (AWARE), Cognitive

Not yet recruiting
  • Stress Disorders, Post-Traumatic
  • Adjunctive writing to amplify response and engagement (AWARE)
  • +2 more
  • Boston, Massachusetts
    National Center for PTSD at VA Boston Healthcare System
Oct 12, 2023

Transfusion-dependent Beta-Thalassemia Trial in Peshawar (Thalidomide)

Completed
  • Transfusion-dependent Beta-Thalassemia
  • Peshawar, Khyber Pakhtunkhwa, Pakistan
    Blood Care Clinic
Nov 19, 2023

Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma Trial in United

Recruiting
  • Acute Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Atlanta, Georgia
  • +13 more
Jan 26, 2023

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023

Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

Not yet recruiting
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Boston, Massachusetts
  • +1 more
Apr 4, 2023

Multiple Myeloma Trial in Torino (velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade

Active, not recruiting
  • Multiple Myeloma
  • velcade subcutaneous melphalan prednisone
  • +2 more
  • Torino, Italy
    A.O.U. Città della Salute e della Scienza di Torino - SC Ematolo
Mar 24, 2022

Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

Not yet recruiting
  • Primary Extranodal Lymphoma
  • DLBCL
  • (no location specified)
Apr 6, 2022

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023